Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 17, 2026

Digital Supply Chain & Logistics Tech Research Report 2026: A $146.92 Billion Market by 2031 from $72 Billion in 2025 with SAP, Oracle, Blue Yonder, DHL, and Schneider Electric Leading

View original at finance.yahoo.com
Digital Supply Chain & Logistics Tech Research Report 2026: A $146.92 Billion Market by 2031 from $72 Billion in 2025 with SAP, Oracle, Blue Yonder, DHL, and Schneider Electric Leading Company Logo The Digital Supply Chain & Logistics Tech Market is anticipated to grow from USD 72 Billion in 2025 to USD 146.92 Billion…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DHL Supply Chain's acquisition of IDS Fulfillment added over 1.3 million square feet of multi-customer warehouse and distribution space across the US

    80% confidence

  • Cloud-based supply chain solutions hold the largest global market share and are expected to grow at a CAGR of more than 13% during the forecast period

    80% confidence

  • In FY2025, India's e-commerce sector achieved a GMV of approximately $14 billion, showing 12% year-on-year growth, and is anticipated to reach $345 billion by 2030

    80% confidence

  • EU GDP was 1.0% higher in real terms in 2024 than in 2023

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com